Combined antiestrogen, antiangiogenic and anti-invasion therapy inhibits primary and metastatic tumor growth in the MMTVneu model of breast cancer.
Treatments available to women with locally advanced breast cancer are unsatisfactory, since most patients succumb to metastatic spread. Therefore, there is a need to devise novel therapeutic combinations that effectively inhibit metastatization and to test them in animal models of breast cancer showing strong similarities with their human counterpart, including the ability to give rise to metastases. With these considerations in mind, tamoxifen (TAM), 4-hydrotamoxifen (4-HT) or liposome-complexed DNA constructs coding for antiangiogenic/anti-invasion proteins (angiostatin, TIMP-2, IFN-alpha(1), sFLT-1) were individually administered to MMTVneu transgenic mice. Significant inhibition of primary tumor growth was obtained with TAM (40% inhibition, P=0.049), angiostatin (85% inhibition, P=0.001) and TIMP-2 (60% inhibition, P=0.015). No lung metastasis was observed in any of these treated mice at 5 months, compared with a rate of 70% in control groups. These observations were the basis for designing a combined treatment with all these compounds. The association of angiostatin, TIMP-2 and TAM was greatly effective at the primary tumor level (90% inhibition, P=0.01). Moreover, all the mice treated with this association were metastasis free at a time point (6 months) in which seven out of nine control mice were either dead from disseminated cancer or showed lung metastasis. This combined therapy could become an important component of anticancer therapy in humans.
D020533:Angiogenesis Inhibitors / Q000235:genetics; D043168:Angiostatins; D000818:Animals; D001943:Breast Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use*; D016326:Extracellular Matrix Proteins / Q000235:genetics; D005260:Female; D015870:Gene Expression; D018734:Genes, erbB-2; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage; D016898:Interferon-alpha / Q000235:genetics; D008175:Lung Neoplasms / Q000517:prevention & control* / Q000556:secondary*; D051379:Mice; D008822:Mice, Transgenic; D023421:Models, Animal; D018995:Myosin Heavy Chains; D024501:Nonmuscle Myosin Type IIB; D010446:Peptide Fragments / Q000235:genetics; D010958:Plasminogen / Q000235:genetics; D013629:Tamoxifen / Q000627:therapeutic use*; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000235:genetics
D020533:Angiogenesis Inhibitors; D020847:Estrogen Receptor Modulators; D016326:Extracellular Matrix Proteins; D016898:Interferon-alpha; D010446:Peptide Fragments; D013629:Tamoxifen; D019716:Tissue Inhibitor of Metalloproteinase-2; D043168:Angiostatins; D010958:Plasminogen; D024501:Nonmuscle Myosin Type IIB; C103815:nonmuscle myosin type IIB heavy chain; D018995:Myosin Heavy Chains